Drug intelligence / Profile preview

beclometasone intravitreal

Development stage: Discontinued
Lead developer: Allergan
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Intravitreal

Overview

Beclometasone intravitreal (AGN208397) is a formulation of the synthetic corticosteroid beclomethasone dipropionate developed for intravitreal injection. It was investigated for the treatment of macular edema associated with retinal vein occlusion and other retinal disorders. The drug acts as an immunosuppressant and steroid receptor agonist, exerting anti-inflammatory effects by modulating gene expression through glucocorticoid receptors. Originally developed by Allergan (later acquired by AbbVie), clinical development reached phase I/II but was discontinued before approval[3][4][6].

Other names: beclomethasone dipropionate intravitrealbeclometasone intravitreous

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on beclometasone intravitreal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beclometasone intravitreal.

Explore the full profile